AUTHORS
Hemalatha Geetharani Rangarajan I, MD, Antonio Pérez Martínez, MD PhD2, Jacques-Emmanuel Galimard3, Arnaud Dalissier4, Monika Mielcarek-Siedziuk5, Kristina Marshall6, Jan Styczynski, PhD7, Peter Bader, MD PhD8, Franca Fagioli9, Ali Al-Ahmari, MD10, Renata Formankova11, Amir Hamidieh, MD12, Katharine Patrick13, Fanny Rialland Battisti14, Herbert Pichler15, Samppa Ryhänen, MD, PhD16, Alexey Maschan, MD17, Marco Zecca, MD18, Francesco Paolo Tambaro, MD,PhD19, Mohammed Essa20, Marc Ansari, MD21, Katharina Kleinschmidt, MD22, Krzysztof Kalwak, PhD, DSc23
AFFILIATIONS
1 Nationwide Children's Hospital, Columbus, Ohio, United States
2 University Hospital La Paz, Madrid, Spain
3 EBMT Paris Study Unit, Paris, France
4 EBMT Paris Study Unit, Paris, France
5 Wroclaw Medical University, Wroclaw, Poland
6 Bristol Royal Hospital for Children, Bristol, United Kingdom
7 Jurasz University Hospital, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
8 Goethe University Frankfurt, Frankfurt, Germany
9 Onco-Ematologia Pediatrica Centro Trapianti Cellule Staminali, Torino, Italy
10 King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
11 Motol and Homolka University Hospital, Prague, Czech Republic
12 Children`s Medical Centre/Tehran University of Medical Sciences, Tehran, Iran
13 Sheffield Children’s hospital, NHS Foundation Trust, Sheffield, United Kingdom
14 CHU Nantes Dept. D`Hematologie, Nantes, France
15 St. Anna Children’s Hospital, Children’s Cancer Research Institute, Medical University of Vienna,, Vienna, Austria
16 Children’s Hospital, University of Helsinki and Helsinki University Hospital, Pediatric Research Center, Helsinki, Finland
17 Federal Research Center for Pediatric Hematology, Moscow, Russian Federation
18 Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
19 AORN IRCCS Santobono Pausilipon, Naples, Italy
20 King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
21 University of Geneva, Geneva, Switzerland
22 University of Regensburg, Regensburg, Germany
23 Wroclaw Medical University, Wroclaw, Poland
ABSTRACT
Background:Treosulfan, with its favorable toxicity profile, is increasingly being considered for conditioning in pediatric patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (HCT). Published comparisons of treosulfan- and busulfan-based conditioning have primarily included recipients of ≥ 2nd HCT. Therefore, we conducted a study comparing outcomes in pediatric patients with AML undergoing 1st allogeneic HCT following either treosulfan or busulfan-based conditioning.
Methods: This retrospective European Society for Blood and Marrow Transplantation (EBMT) Pediatric Diseases Working Party (PDWP) study included children (<18 years) with de novo AML in first or second complete remission (CR1/CR2) who underwent 1st allogeneic HCT between 2014 and 2022 at 37 centers following busulfan/cyclophosphamide (BuCy), Busulfan/cyclophosphamide/melphalan (BuCyMel), or treosulfan/fludarabine/thiotepa (TreoFluTT) conditioning. Recipients of cord blood, haploidentical and <9/10 mismatched donor transplants were excluded. We compared the following outcomes among the three groups: leukemia-free survival (LFS), overall survival (OS), non-relapse mortality (NRM), graft-versus-host disease-free survival (GRFS), relapse incidence (RI), incidence of acute graft-versus-host disease (aGVHD), chronic GVHD (cGVHD) and veno-occlusive disease (VOD).
Results: A total of 400 patients (58% male), with a median age of 9.1 years (IQR, 3.6–13.5) met study criteria. Of these, 129 received BuCy, 162 received BuCyMel, and 109 received TreoFluTT. Baseline characteristics were generally similar among the three groups (BuCy vs BuCyMel vs TreoFluTT), with a few significant differences. BuCyMel recipients were younger (median age: 10.2 vs. 6.8 vs. 10.2 years; p=0.002). A greater proportion of BuCy recipients received bone marrow grafts (73.6% vs. 67.9% vs. 44.0%; p<0.001), whereas peripheral blood stem cell grafts were used more often in the TreoFluTT group (26.4% vs. 31.2% vs. 56.0%; p<0.001). TreoFluTT recipients were more likely to have a performance score ≤80 (10.9% vs. 10.5% vs. 45.4%; p<0.001). In vivo T-cell depletion with serotherapy was used less frequently in the BuCyMel cohort (58.1% vs. 27.2% vs. 40.4%; p<0.001), while BuCy recipients were more likely to receive grafts from matched sibling donors (55.0% vs. 25.2% vs. 28.4%; p<0.001). The median follow-up for the entire cohort was 4.9 years (95% CI, 4.5–5.2 years). The 2-year LFS, OS, GRFS, RI, and NRM for the entire cohort were 73.9% (95% CI, 69.2–77.9%), 81.0% (95% CI, 76.8–84.5%), 64% (95% CI, 59.1–68.6%), 19.6% (95% CI, 15.8–23.6%), and 6.5% (95% CI, 4.4–9.3%), respectively. The cumulative incidence of grade II–IV aGVHD by D+100 was 25.8% (95% CI, 21.6–30.2%), while the cumulative incidence of cGVHD at 2 years was 16.3% (95% CI, 12.9–20.2%). The 2-year cumulative incidence of VOD was 11.0% (95% CI, 8.2–14.3%) with the lowest incidence in TreoFluTT group (17.2% vs 11.7% vs 2.8%). In univariable analyses, compared with TreoFluTT, the risk of VOD was significantly higher with BuCy (HR 6.58, 95% CI 1.67–22.0; p=0.002) and BuCyMel (HR 4.36, 95% CI 1.29–14.73; p=0.02). Among the 98 deaths, the predominant cause of death was disease relapse (70.4%). In multivariable analysis, compared with TreoFluTT, neither BuCy nor BuCyMel was associated with significant differences in leukemia-free survival (LFS) (BuCy: HR 1.55, p=0.10; BuCyMel: HR 1.21, p=0.45) or overall survival (OS) (BuCy: HR 1.42, p=0.24; BuCyMel: HR 1.28, p=0.38). Likewise, no significant differences were observed for NRM (BuCy: HR 1.46, p=0.55; BuCyMel: HR 2.91, p=0.06), GRFS (BuCy: HR 1.37, p=0.18; BuCyMel: HR 1.31, p=0.22), or RI (BuCy: HR 1.57, p=0.12; BuCyMel: HR 0.90, p=0.72). The incidence of acute and chronic GVHD was also not different across conditioning regimens (data not shown). Additionally OS was lower in patients transplanted in CR2 vs CR1,while increasing age was associated with higher NRM and cGVHD. The latter was significantly lower in matched unrelated donor recipients
Conclusion: In this study, conditioning with BuCy, BuCyMel, and TreoFluTT resulted in similar post-transplant outcomes in children with AML. Notably, TreoFluTT was associated with a significantly reduced risk of VOD. The ongoing prospective randomized trial comparing BuCyMel and TreoFluTT in pediatric AML is expected to provide more robust evidence regarding differences between these conditioning approaches.
DISCLOSURES
Hemalatha Geetharani Rangarajan I, MD: EDITAS - Other (including travel support); Medexus - Consultancy (Includes expert testimony); BEAM therapeutics - Consultancy (Includes expert testimony); Vertex Therapeutics - Consultancy (Includes expert testimony); NMDP Data Safety Monitoring Board CD33 CAR T (unpaid) - Consultancy (Includes expert testimony)